Case report: Response to everolimus in a patient with platinum resistant, high grade serous ovarian carcinoma with biallelic TSC2 inactivation

Case report: Response to everolimus in a patient with platinum resistant, high grade serous ovarian carcinoma with biallelic TSC2 inactivation

BackgroundPatients with platinum-resistant recurrent high grade serous ovarian carcinoma have poor outcomes and limited treatment options.Case presentationWe present a case of a 48-year-old woman with platinum-resistant high grade serous ovarian carcinoma harboring the pathogenic TSC2 R611Q variant...

Full description

Bibliographic Details
Main Authors: Mariko Peterson, David L. Kolin, Panagiotis A. Konstantinopoulos
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
platinum resistant ovarian cancer
mTOR inhibitor
TSC1 and TSC2 mutations
everolimus
letrozole
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1357980/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1357980/full

Similar Items